<p>Because of the possibility of an anaphylactoid reaction, lymphoma patients should be treated with 2 units or less for the first 2 doses. If no acute reaction occurs, then the regular dosage schedule may be followed.<br />
<br />
<strong>Squamous cell carcinoma, non-Hodgkin&rsquo;s lymphoma, testicular carcinoma</strong>: 0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.<br />
<br />
<strong>Hodgkin&rsquo;s disease</strong>: 0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly. After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given.<br />
<br />
Pulmonary toxicity of Bleomycin sulfat appears to be dose-related with a striking increase when the total dose is over 400 units. Total doses over 400 units should be given with great caution.<br />
<br />
<strong>Note</strong>: When Bleomycin sulfat is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses.<br />
<br />
Improvement of Hodgkin&rsquo;s disease and testicular tumors is prompt and noted within 2 weeks. If no improvement is seen by this time, improvement is unlikely. Squamous cell cancers respond more slowly, sometimes requiring as long as 3 weeks before any improvement is noted.<br />
<br />
<strong>Malignant Pleural Effusion</strong>: 60 units administered as a single dose bolus intrapleural injection</p>